Expanded HD (HDx)
Worldwide evidence
Delivering meaningful innovation through
evidence-based therapy
Albumin removal during HDx treatment is 3 grams on average and limited to between 1 and 4 grams per treatment.1 Further, HDx therapy does not impact plasma albumin level to a clinically significant extent.2
HDx with the Theranova dialyser provides superior removal of large middle molecules (25 kDa to < 60 kDa) compared to conventional HD and high-volume HDF modalities.1
Pre-dialysis levels of beta 2 microglobulin and kappa and lambda free light chains were reduced after 3 and 6 months with HDx therapy using the MCO dialyser in a multi-centric observational study of 41 HD patients.3
Restless Leg Syndrome criteria are reduced approximately 50% after 6 months for prevalent HD patients in a large observational study by Baxter.4 A smaller before-after study found no difference in patient-reported symptom burden.2
A robust evidence generation effort underpins meaningful innovation.
Inflammation – A Tale of Death, Doom & Dialysis
Watch the webinar series with Prof. Chris McIntyre
HDx | Performance Snapshot
1 – From launch through Jun 2020. 2 – CY2019. 3 – YTD2020 assuming 152 Tx/Yr/Pt. 4 – Source: GRMF
MEET THE EXPERTS
Click here to learn more >
- Kirsch AH, et al. Performance of hemodialysis with novel medium cut-off dialyzers. Nephrol Dial Transpl 2017; 32(1):165-72.
- Krishnasamy R et al. Trial evaluating mid cut-off value membrane clearance of albumin and light chains in hemodialysis patients (REMOVAL-HD): a safety and efficacy study. ASN 2018 Kidney Week Abstract TH-PO353.
- Cantaluppi V et al. Removal of large-middle molecules on expanded hemodialysis (HDx): a multicentric observational study of 6 months follow-up. ASN 2018 Kidney Week Abstract TH-PO357.
- Sanabria M et al. Quality of life reported by patients with expanded hemodialysis by the Theranova dialyzer in RTS Colombia. ASN 2018 Kidney Week Abstract TH-PO296.